Verrica Pharmaceuticals Inc.
VRCANasdaq
$5.59
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↓ -33.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$119.1M
Enterprise Value
$98.5M
P/E
—
P/S
3.2
P/B
7.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$37.2M
Net Income (TTM)
-$17.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-37.0%
Net Margin
-48.0%
ROE
-111.1%
ROIC
—
Debt / Equity
—
Net Cash
$20.6M
Return 1Y
-34.6%
Company profile
Verrica Pharmaceuticals Inc. develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; VP-103 for treating plantar warts.
- CEO
- Ted White
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Pennsylvania
- Website
- verrica.com
Management & directors
- Kirby John J.Interim CFO
- Rieger JaysonCEO and President
- Rosenberg Noah L.CMO
- Zawitz DavidChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
VRCA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.0M↑ +46.1%
Diluted EPS-$0.45↓ -56.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $12.0M | $9.0M | $5.1M | $7.6M | $35.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$40.2M | -$30.9M | -$21.3M | -$65.8M | -$65.9M | -$12.2M |
| Net income | -$42.7M | -$35.1M | -$24.5M | -$67.0M | -$76.6M | -$17.9M |
| Diluted EPS | — | -$1.30 | -$0.72 | -$1.48 | -$14.78 | -$1.68 |
| Operating cash flow | -$30.2M | -$27.6M | -$18.6M | -$38.6M | -$60.9M | -$17.6M |
| Free cash flow | -$31.7M | -$28.5M | -$19.0M | -$38.9M | -$61.0M | -$17.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -257.6% | -235.8% | -1283.4% | -871.3% | -34.2% |
| Net margin | — | -292.3% | -271.1% | -1307.6% | -1012.4% | -50.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | -$1.8M | $344,000.00 | $3.4M | $12.7M | $14.3M | $5.1M | $5.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.2M | -$20.7M | -$11.4M | -$8.1M | $1.5M | $1.6M | -$7.2M | -$9.7M |
| Net income | -$17.2M | -$22.9M | -$16.2M | -$9.7M | $204,000.00 | -$274,000.00 | -$8.1M | -$9.7M |
| Diluted EPS | -$3.70 | -$4.88 | -$5.76 | -$1.03 | $0.02 | -$0.03 | -$0.64 | -$0.45 |
| Operating cash flow | -$16.4M | -$8.6M | -$16.1M | -$12.7M | -$10.0M | $9.7M | -$4.6M | -$9.2M |
| Free cash flow | -$16.4M | -$8.6M | -$16.1M | — | — | $9.7M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -293.7% | 1162.5% | -3316.9% | -236.4% | 11.9% | 11.3% | -141.2% | -193.4% |
| Net margin | -332.0% | 1283.5% | -4716.0% | -283.3% | 1.6% | -1.9% | -158.8% | -192.8% |
Company news
May 28, 2026
May 13, 2026
- 68d agoVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQfinance.yahoo.com
- 68d agoTranscript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Callfinance.yahoo.com
- 68d agoVerrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...finance.yahoo.com
- 68d agoVerrica Pharmaceuticals Q1 Earnings Call Highlightsmarketbeat.com
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-23 | Kirby John J.· Interim CFO | Award | 10,000 | $0.00 | $0.00 | filing |
| 2025-11-25 | Manning Paul B | Buy | 2,750,762 | $4.24 | $11.7M | filing |
| 2025-11-25 | Manning Paul B | Buy | 1,375,380 | $4.24 | $5.8M | filing |
| 2025-11-25 | Rieger Jayson· CEO and President | Buy | 94,311 | $4.24 | $400,114.42 | filing |
| 2025-11-25 | Zawitz David· Chief Operating Officer | Buy | 10,000 | $4.24 | $42,425.00 | filing |
| 2025-11-25 | Kirby John J.· Interim CFO | Buy | 3,536 | $4.24 | $15,001.48 | filing |
| 2025-11-25 | Rosenberg Noah L.· CMO | Buy | 2,357 | $4.24 | $9,999.57 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.